Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
RNA therapeutics
Advertisement
ARTHEx Biotech Advances ATX-01 for Myotonic Dystrophy
VALENCIA, Spain, May 27, 2026 ARTHEx Biotech, a clinical-stage biotechnology company focused on RNA-based therapeutics for neuromuscular diseases, has...
TransCode Starts Phase 2a Trial for TTX-MC138
BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...
Atisama Advances RB042 Phase 1 Trial and Strengthens Leadership
Melbourne, Australia – May 15, 2026 Atisama Therapeutics, formerly known as Rage Bio, announced significant progress in the ongoing...
AIRNA Showcases RNA Editing Advances at ASGCT 2026
CAMBRIDGE, Mass., May 12, 2026 AIRNA announced new preclinical findings at the 2026 American Society of Gene and Cell...
Advertisements
Mirai Bio Advances In Vivo CAR-T Platform at ASGCT
CAMBRIDGE, Mass., May 12, 2026 Mirai Bio unveiled new preclinical data at the American Society of Gene and Cell...
ArteraAI Breast Gains FDA Clearance for Cancer Risk
SAN FRANCISCO, May 6, 2026 Artera announced that the U.S. Food and Drug Administration (FDA) has granted clearance for...
GSK Signs $1B SiranBio siRNA Cardiometabolic Deal
SUZHOU, China, May 6, 2026 SiranBio announced a major global licensing agreement with GSK for its investigational siRNA therapeutic...
Sail Biomedicines Advances In Vivo eRNA CAR-T Data
CAMBRIDGE, Mass., April 27, 2026 Sail Biomedicines announced it will present new preclinical data supporting its In Vivo eRNA™...
Atrium Therapeutics Earns $15M Milestone from Bristol Myers Squibb
San Diego, California, USA – April 23, 2026 Atrium Therapeutics announced it has achieved a $15 million development milestone...
Advertisement
